目的 評價2011-2016年天津市腫瘤醫(yī)院乳腺癌內(nèi)分泌治療藥物的使用情況。方法 調(diào)取天津市腫瘤醫(yī)院2011-2016年乳腺癌內(nèi)分泌治療藥物的相關(guān)用藥信息，對藥品使用金額、用藥頻度（DDDs）、日均費用（DDC）及藥品排序比（B/A）進行統(tǒng)計分析。結(jié)果 2011-2016年天津市腫瘤醫(yī)院乳腺癌內(nèi)分泌治療藥物的臨床應(yīng)用呈逐年上升趨勢。芳香酶抑制劑（AIs）使用金額的占比大于70%。各類藥品的DDDs整體亦呈現(xiàn)增長趨勢，依西美坦（進口）增幅最大。各類藥品的DDC值穩(wěn)中有降，大部分乳腺癌內(nèi)分泌治療藥物的B/A值接近于1.00，使用金額和DDDs同步性較好。結(jié)論 天津市腫瘤醫(yī)院乳腺癌內(nèi)分泌藥物使用基本合理，符合安全、有效、經(jīng)濟、方便的原則。

Objective To investigate the utilization of breast cancer endocrine therapy drugs in Tianjin Cancer Hospital from 2011 to 2016. Methods The utilization information of breast cancer endocrine therapy drugs in Tianjin Cancer Hospital from 2011 to 2016 was extracted, and the consumption sum of drugs, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2011 to 2016, clinical application of endocrine therapy for breast cancer increased year by year. The proportion of AIs was more than 70%. DDDs of various drugs also showed an overall trend, while ethoxetron (import) increased the most. DDC values of all kinds of drugs were steadily lower. Most of the breast cancer endocrine therapy drugs B/A was close to 1.00, indicating that the synchronism was better. Conclusion The utilization of breast cancer endocrine therapy in Tianjin Cancer Hospital is reasonable, according with the principle of safety, effectiveness, economy, and convenience.